-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
Lyra Therapeutics, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2019 to Q2 2025.
- Lyra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2025 was -$7.44M, a 84.5% increase year-over-year.
- Lyra Therapeutics, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2025 was -$38.8M, a 61.7% increase year-over-year.
- Lyra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2024 was -$93.4M, a 49.1% decline from 2023.
- Lyra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$62.7M, a 13.4% decline from 2022.
- Lyra Therapeutics, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$55.3M, a 27% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)